Medicine recalls
|
| |
| Singapore: Recall of two batches of Zerbaxa® [ceftolozane and tazobactam] for injection (1.5 g) 1g／0.5g 10×20ml vial |
| |
The Health Sciences Authority (HSA) announces that MSD Pharma (Singapore) Pte Ltd is recalling two batches of Zerbaxa [ceftolozane and tazobactam] for injection (1.5 g) 1g/0.5g 10x20ml vial (batch numbers: S039205, S034858) at retail-level due to out of specification of sterility tests.
Please refer to the following website in HSA for details:
http://www.hsa.gov.sg/announcements/product-recall/recall-of-two-batches-of-zerbaxa-ceftolozane-and-tazobactam-for-injection-(1.5-g)-1g-0.5g-10-20ml-vial
In Hong Kong, Zerbaxa Powder For Concentrate For Solution For Infusion 1g/0.5g (HK-65156) is a pharmaceutical product registered by Merck Sharp & Dohme (Asia) Ltd (MSD), and is a prescription-only medicine. As confirmed with MSD, one of the affected batches (S034858) has been imported into Hong Kong.
On 17 Dec 2020, the Department of Health (DH) endorsed MSD to recall all batches of Zerbaxa Powder For Concentrate For Solution For Infusion 1g/0.5g (HK-65156) from the market (including batch S034858) due to a potential quality issue. A press statement was issued on the same day. The DH will continue to monitor the recall.
Related news was previously issued by the United Kingdom Medicines and Healthcare products Regulatory Agency, and Health Canada; and was posted on the Drug Office website on 17 Dec 2020 and 18 Dec 2020.
Ends/ Monday, December 28, 2020
Issued at HKT 15:00
|
| |
|
